GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (FRA:GOV) » Definitions » Other Net Income (Loss)

Insulet (FRA:GOV) Other Net Income (Loss) : €-0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Other Net Income (Loss)?

Insulet's Other Net Income (Loss) for the three months ended in Mar. 2024 was €0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0 Mil.

Insulet's quarterly Other Net Income (Loss) declined from Sep. 2023 (€0 Mil) to Dec. 2023 (€-0 Mil) but then increased from Dec. 2023 (€-0 Mil) to Mar. 2024 (€0 Mil).

Insulet's annual Other Net Income (Loss) stayed the same from Dec. 2021 (€0 Mil) to Dec. 2022 (€0 Mil) but then declined from Dec. 2022 (€0 Mil) to Dec. 2023 (€-0 Mil).


Insulet Other Net Income (Loss) Historical Data

The historical data trend for Insulet's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Other Net Income (Loss) Chart

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insulet Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Insulet Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insulet Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Insulet's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (FRA:GOV) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Insulet (FRA:GOV) Headlines

No Headlines